David Quinn MD
Genitourinary Oncology
Medical Director of the Norris Cancer Hospital; Head, section of Genitourinary Medical Oncology; Associate Professor of Medical Oncology, USC School of Medicine
Join to View Full Profile
1441 Eastlake AveSte 3440Los Angeles, CA 90089
Phone+1 323-865-3956
Fax+1 323-865-0061
Dr. Quinn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Quinn is an oncologist in Los Angeles, CA and is affiliated with multiple hospitals in the area, including Keck Hospital of USC, USC Norris Comprehensive Cancer Center, and USC Norris Comprehensive Cancer Center. He received his medical degree from University of New South Wales Faculty of Medicine and has been in practice 30 years. He specializes in genitourinary oncology and is experienced in urologic oncology and general medical oncology.
Education & Training
University of New South Wales Faculty of MedicineClass of 1987
Certifications & Licensure
CA State Medical License 2004 - 2027
American Board of Radiology Therapeutic Medical Physics
Awards, Honors, & Recognition
- Best Doctors for Cancer Best Doctors
- Top Doctors Castle Connolly
- CMS Meaningful Use Stage 2 Certification PowerChart (CQM), Cerner Corporation, 2014-2017
Clinical Trials
- S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Start of enrollment: 2006 Aug 01
- Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma Start of enrollment: 2004 Nov 01
- Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. Start of enrollment: 2001 Mar 01
Publications & Presentations
PubMed
- Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.Anishka A D'Souza, Susan G Groshen, Denice Tsao-Wei, Nora Ruel, Tanya B Dorff
Current Problems in Cancer. 2026-05-07 - 1 citationsEfficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.Bob T Li, Leena Gandhi, Vignesh Ravichandran, Benjamin Besse, Julien Mazières
Clinical Lung Cancer. 2026-03-01 - Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.Ronald de Wit, David J Vaughn, Yves Fradet, Lawrence Fong, Miguel A Climent
European Urology. 2025-11-01
Journal Articles
- Axitinib Versus Placebo as an Adjuvant Treatment for Renal Cell Carcinoma: Results from the Phase III, Randomized ATLAS TrialV Master, D I Quinn, Annals of Oncology
- Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall SurvivalEric J Small, David I Quinn, Clinical Cancer Research
- pembrolizumabQuinn, new england, 2017
Press Mentions
Ground Broken on New Medical FacilityMay 3rd, 2019
Intermittent Androgen Deprivation Not Equivalent to Continuous Treatment for Prostate Cancer, May Compromise SurvivalApril 5th, 2013
Prostate Cancer Study Suggests Shorter TreatmentsFebruary 12th, 2016
Professional Memberships
- Member
- Member
- Fellow
- ESMOMember
- Australasian College of PhysiciansFellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
